BioWin and MEDVIA are two Belgian organizations which support and promote health innovation in Wallonia and Flanders. This year, these two clusters have come together to jointly organize the event Science for health on the topic of ‘biology meets technology’. In this dual interview, Ann Van Gysel (MEDVIA) and Sylvie Ponchaut (BioWin) discuss the differences between their regions and how they are working to improve cross-border collaboration in Belgium.
The AIPLANT project aims to reduce complications from dental implant surgery using AI-based preoperative planning. The project is a collaboration between the Centre for Dentomaxillofacial Imaging at UZ Leuven, AI startup Relu, and Xentro Dental.
Patient data is a treasure trove of information, vital to tailoring individual care pathways and generating profound insights to enhance healthcare more broadly. However, achieving interoperability among the diverse systems employed by various healthcare providers remains a critical challenge. Data standards like FHIR can help to streamline the secure exchange and seamless integration of healthcare data across these different systems. This article will take you through the FHIR framework and how it could be used by your organization.
This year, Science for health will explore the inspiring innovations at the interface of biology and technology. The event will bring together academics, industry leaders, and policymakers to explore the newest treatment platforms and factories of the future. BioVox spoke to Werner Verbiest, member of the event’s Scientific Committee, about the topic and why collaboration is so key right now.
Studies of a drug's effectiveness and safety don’t end with clinical trials – they extend beyond market access when the true value of a drug is demonstrated in a real-world setting. Based on this information, factors such as availability, pricing, and reimbursement are adjusted. To study the actual worth of a treatment, we require real-world data (RWD) from a large and diverse patient population. By actively sharing this information with stakeholders, we can fuel further research and innovation, and even help to inform decision-making on a population level. But in order to unlock the full potential of our patient data, all members of the ecosystem have to work together.
Belgian Prof. Jan Rabaey has spent the past 35 years conducting pioneering tech research at the University of California at Berkeley. His groundbreaking electronics work has been used in a range of modern devices, including the iPad, brain-computer interfaces, and wireless sensor nodes used for the Internet of Things. The ongoing theme of his work has been miniaturization and connection, which he is now using to link technology and people like never before.
Flanders is home to one of the world’s most innovative agrifood clusters, and Johan Cardoen has been a central figure in that ecosystem for over three decades. From leading positions in agtech startups to the Managing Director of VIB, Cardoen has run the gamut of Flemish biotech. Interested in his decades of firsthand experience in the sector, we spoke with Cardoen about his views on the past, present, and future of sustainable agriculture.
Instantly turning water into beer may sound like a biblical miracle, but that’s exactly what Belgian start-up Bar.on is now doing. Their ‘molecular beer printer’ takes mere seconds to turn water into different styles of beer, with customized bitterness, alcohol content, fruitiness, and sweetness. Backed by science, the company is on a mission to make the beer industry more sustainable and hopes to soon roll out its molecular beer mixing technology to different markets.
The pharma, biotech and medtech industries offer a wealth of job and career opportunities, but recent graduates and early-career professionals are often unaware of the many options available to them in the life sciences. This article briefly overviews the many job possibilities in the industry, including a link to a recently published book for those wanting an insider’s guide to further employment prospects.
OHMX.bio provides innovative omics solutions using state-of-the-art sequencing and mass spectrometry platforms. Specializing in expression analysis (RNA-seq and RIBO-seq) and epigenetic profiling, as well as companion diagnostics, the company uses second- and third-generation sequencing technology to enable scientific insights and build assays for better drug and therapy development. With both a wet lab and dry lab in house, OHMX.bio offers a full-circle service to biotech and pharma partners.
BioWin and MEDVIA are two Belgian organizations which support and promote health innovation in Wallonia and Flanders. This year, these two clusters have come together to jointly organize the event Science for health on the topic of ‘biology meets technology’. In this dual interview, Ann Van Gysel (MEDVIA) and Sylvie Ponchaut (BioWin) discuss the differences between their regions and how they are working to improve cross-border collaboration in Belgium.
The AIPLANT project aims to reduce complications from dental implant surgery using AI-based preoperative planning. The project is a collaboration between the Centre for Dentomaxillofacial Imaging at UZ Leuven, AI startup Relu, and Xentro Dental.
Patient data is a treasure trove of information, vital to tailoring individual care pathways and generating profound insights to enhance healthcare more broadly. However, achieving interoperability among the diverse systems employed by various healthcare providers remains a critical challenge. Data standards like FHIR can help to streamline the secure exchange and seamless integration of healthcare data across these different systems. This article will take you through the FHIR framework and how it could be used by your organization.
This year, Science for health will explore the inspiring innovations at the interface of biology and technology. The event will bring together academics, industry leaders, and policymakers to explore the newest treatment platforms and factories of the future. BioVox spoke to Werner Verbiest, member of the event’s Scientific Committee, about the topic and why collaboration is so key right now.
Studies of a drug's effectiveness and safety don’t end with clinical trials – they extend beyond market access when the true value of a drug is demonstrated in a real-world setting. Based on this information, factors such as availability, pricing, and reimbursement are adjusted. To study the actual worth of a treatment, we require real-world data (RWD) from a large and diverse patient population. By actively sharing this information with stakeholders, we can fuel further research and innovation, and even help to inform decision-making on a population level. But in order to unlock the full potential of our patient data, all members of the ecosystem have to work together.
Belgian Prof. Jan Rabaey has spent the past 35 years conducting pioneering tech research at the University of California at Berkeley. His groundbreaking electronics work has been used in a range of modern devices, including the iPad, brain-computer interfaces, and wireless sensor nodes used for the Internet of Things. The ongoing theme of his work has been miniaturization and connection, which he is now using to link technology and people like never before.
Flanders is home to one of the world’s most innovative agrifood clusters, and Johan Cardoen has been a central figure in that ecosystem for over three decades. From leading positions in agtech startups to the Managing Director of VIB, Cardoen has run the gamut of Flemish biotech. Interested in his decades of firsthand experience in the sector, we spoke with Cardoen about his views on the past, present, and future of sustainable agriculture.
Instantly turning water into beer may sound like a biblical miracle, but that’s exactly what Belgian start-up Bar.on is now doing. Their ‘molecular beer printer’ takes mere seconds to turn water into different styles of beer, with customized bitterness, alcohol content, fruitiness, and sweetness. Backed by science, the company is on a mission to make the beer industry more sustainable and hopes to soon roll out its molecular beer mixing technology to different markets.
The pharma, biotech and medtech industries offer a wealth of job and career opportunities, but recent graduates and early-career professionals are often unaware of the many options available to them in the life sciences. This article briefly overviews the many job possibilities in the industry, including a link to a recently published book for those wanting an insider’s guide to further employment prospects.
OHMX.bio provides innovative omics solutions using state-of-the-art sequencing and mass spectrometry platforms. Specializing in expression analysis (RNA-seq and RIBO-seq) and epigenetic profiling, as well as companion diagnostics, the company uses second- and third-generation sequencing technology to enable scientific insights and build assays for better drug and therapy development. With both a wet lab and dry lab in house, OHMX.bio offers a full-circle service to biotech and pharma partners.